SUCCESS RATES OF
TIL THERAPY
What the numbers actually mean β read honestly, by cancer type, for patients who want to understand the real evidence base.
What Success Actually Means in Clinical Research
Objective response rate (ORR): percentage of patients whose tumors shrank by a defined threshold. Complete response (CR): tumor disappeared on imaging. Partial response (PR): shrank by at least 30%. Durable response: lasted six months or more.
βA 30% response rate in patients who had run out of options is not a footnote β it is a lifeline for the right patient.β
Response Data by Cancer Type
Melanoma (FDA Approved)
C-144-01 pivotal trial in heavily pre-treated patients who failed prior immunotherapy
Cervical Cancer
Recurrent/metastatic disease after prior treatment failure; responses proved durable
Other Solid Tumors
Lung, head and neck, ovarian β encouraging early signals, evidence still building
Reading the Evidence Honestly
A 31-36% response rate means most patients in the trial did not respond. That is worth stating directly. What matters is the context: these were patients who had already tried and progressed through multiple treatment lines. In that setting, a real and durable response for one in three carries genuine clinical weight.
Factors That Influence Outcomes
Manufacturing Quality
Center experience and the quality of cell expansion directly affect what is infused β and outcomes differ meaningfully between programs.
Patient Physical Condition
Better performance status and organ health at treatment start correlate with stronger immune response and better tolerance of conditioning.
Frequently Asked Questions
TIL Therapy Outcomes
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want Outcomes Data Relevant to Your Specific Cancer?
Upload your medical reports for a specialist case evaluation. We will match you with clinical evidence and programs most relevant to your exact diagnosis and treatment history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.